^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PP2

i
Other names: PP2, AG1879
Company:
Pfizer, University of Michigan
Drug class:
Src kinase inhibitor
5ms
Identifying proteomic risk factors for overall, aggressive, and early onset prostate cancer using Mendelian Randomisation and tumour spatial transcriptomics. (PubMed, EBioMedicine)
Our findings emphasise the importance of proteomics for improving our understanding of prostate cancer aetiology and of opportunities for novel therapeutic interventions. Additionally, we demonstrate the added benefit of in-depth functional analyses to triangulate the role of risk proteins in the clinical aggressiveness of prostate tumours. Using these integrated methods, we identify a subset of risk proteins associated with aggressive and early onset disease as priorities for investigation for the future prevention and treatment of prostate cancer.
Journal
|
TPM3 (Tropomyosin 3) • PRSS3 (Serine Protease 3)
|
PP2
8ms
A histone methylation-MAPK signaling axis drives durable epithelial-mesenchymal transition in hypoxic pancreatic cancer. (PubMed, Cancer Res)
Furthermore, hypoxia reduced histone demethylase KDM2A activity, suppressed PP2 family phosphatase expression, and activated MAPKs to post-translationally stabilize histone methyltransferase NSD2, leading to an H3K36me2-dependent EMT in which hypoxia-inducible factors played only a supporting role. Hypoxia-driven EMT could be antagonized in vivo by combinations of MAPK inhibitors. Collectively, these results suggest hypoxia promotes durable EMT in PDAC by inducing a histone methylation-MAPK axis that can be effectively targeted with multi-drug therapies, providing a potential strategy for overcoming chemoresistance.
Journal • Epigenetic controller
|
NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
PP2